This document is an excerpt from the EUR-Lex website
Document 32023M11026
Commission Decision of 03/03/2023 declaring a concentration to be compatible with the common market (Case No COMP/M.11026 - PARTNERS GROUP / GHO / STERLING PHARMA) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic)
Id-Deċiżjoni tal-Kummissjoni ta' 03/03/2023 li tiddikjara konċentrazzjoni hija kompatibbli mas-suq komuni (il-Każ Nru COMP/M.11026 - PARTNERS GROUP / GHO / STERLING PHARMA) skond ir-Regolament tal-Kunsill (KE) Nru 139/2004 (It-test bl-Ingliż biss huwa awtentiku)
Id-Deċiżjoni tal-Kummissjoni ta' 03/03/2023 li tiddikjara konċentrazzjoni hija kompatibbli mas-suq komuni (il-Każ Nru COMP/M.11026 - PARTNERS GROUP / GHO / STERLING PHARMA) skond ir-Regolament tal-Kunsill (KE) Nru 139/2004 (It-test bl-Ingliż biss huwa awtentiku)
In force